Reviews:
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions
PDF | Full Text | How to cite
Ricardo Costa1, Cesar A. Santa-Maria1,2, Giovanna Rossi2, Benedito A. Carneiro1,2, Young Kwang Chae1,2, William J. Gradishar1,2, Francis J. Giles1,2, Massimo Cristofanilli1,2
1Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, United States of America
2Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States of America
Correspondence to:
Ricardo Costa, email: ricardo.costa@northwestern.edu
Keywords: inflammatory breast cancer, targeted therapy, immunotherapy
Received: September 26, 2016 Accepted: November 07, 2016 Published: December 02, 2016
ABSTRACT
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, which accounts for approximately 3% of cases of breast malignancies. Diagnosis relies largely on its clinical presentation, and despite a characteristic phenotype, underlying molecular mechanisms are poorly understood. Unique clinical presentation indicates that IBC is a distinct clinical and biological entity when compared to non-IBC. Biological understanding of non-IBC has been extrapolated into IBC and targeted therapies for HER2 positive (HER2+) and hormonal receptor positive non-IBC led to improved patient outcomes in the recent years. This manuscript reviews recent discoveries related to the underlying biology of IBC, clinical progress to date and suggests rational approaches for investigational therapies.